Moving Forward With FluMist Quadrivalent

Our Commitment to Follow the Science Continues

A new strain selection process was used for the replacement A/H1N1 strain in FluMist Quadrivalent

  • Previous A/Bolivia strain did not replicate well and contributed to lower-than-expected VE1
  • Adopted a new strain selection process which identified A/Slovenia as the replacement H1N1 strain for the 2017/2018 flu season1
  • In a pediatric shedding and immunogenicity study in 2- to <4-year-olds, the current A/Slovenia strain was compared to the prior A/Bolivia strain1*
    • A/Slovenia elicited a serum antibody response in significantly more children than the previously used A/Bolivia formulation
    • This study was not designed to evaluate vaccine effectiveness
  • The antibody response to A/Slovenia was similar when compared to historic data from the pre-pandemic (2009) highly effective A/New Caledonia strain2,3

*A/Bolivia was the A/H1N1 strain used in the 2014/2015, 2015/2016, and 2016/2017 FluMist Quadrivalent formulations. A/Slovenia replaced A/Bolivia in 2017/2018.

The percentage of patients with hemagglutination inhibition (HAI) antibody seroconversion was 23.4% with the A/Slovenia formulation vs 5.4% with the A/Bolivia quadrivalent formulation (P=0.006) after dose 1, and 45.2% vs 12.5% (P<0.001) respectively, after dose 2.

Offer your patients an intranasal influenza vaccine recommended by the ACIP and CDC.

Order FluMist Quadrivalent today for the 2018/2019 season.

Important Safety Information

  • FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy

  • In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist

  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing

  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks

  • FLUMIST QUADRIVALENT has not been studied in immunocompromised persons

  • The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established

  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine

  • FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine

  • The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported were runny nose or nasal congestion in persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat


FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

Please see full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.